These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 6588639)

  • 1. Serum erythropoietin (ESF) levels and erythroid progenitors (CFU-Es) of patients with chronic myeloproliferative disorders.
    Fukushima Y; Miura I; Takahashi T; Fukuda M; Yoshida K; Yamaguchi A; Miura AB
    Tohoku J Exp Med; 1984 Apr; 142(4):399-407. PubMed ID: 6588639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [On the existence of a myeloproliferative factor in patients with a myeloproliferative syndrome (author's transl)].
    Essers U; Nowak H
    Blut; 1979 Aug; 39(2):107-15. PubMed ID: 289427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders.
    Hibbin JA; Njoku OS; Matutes E; Lewis SM; Goldman JM
    Br J Haematol; 1984 Jul; 57(3):495-503. PubMed ID: 6743569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopathologic findings in the myeloproliferative disorders.
    Dickstein JI; Vardiman JW
    Semin Oncol; 1995 Aug; 22(4):355-73. PubMed ID: 7638633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Megakaryocytopoiesis in myeloproliferative disorders].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1992; 23(2 Suppl 1):19-22. PubMed ID: 1488868
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum erythropoietin titers in hematological malignancies and related diseases.
    Urabe A; Mitani K; Yoshinaga K; Iki S; Yagisawa M; Ohbayashi Y; Takaku F
    Int J Cell Cloning; 1992 Nov; 10(6):333-7. PubMed ID: 1460322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders.
    Brodsky I; Kahn SB; Ross EM; Petkov G
    Cancer; 1972 Dec; 30(6):1444-50. PubMed ID: 4509103
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating pluripotent haemopoietic cells in patients with myeloproliferative disorders.
    Douer D; Fabian I; Cline MJ
    Br J Haematol; 1983 Jul; 54(3):373-81. PubMed ID: 6574788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet defects in the myeloproliferative disorders.
    Inceman S; Tangün Y
    Ann N Y Acad Sci; 1972 Oct; 201():251-61. PubMed ID: 4509685
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3.
    Kobayashi S; Teramura M; Hoshino S; Motoji T; Oshimi K; Mizoguchi H
    Br J Haematol; 1993 Apr; 83(4):539-44. PubMed ID: 7686030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of a myeloproliferative factor in patients with polycythemia vera and agnogenic myeloid metaplasia. I. Expansion of the erythropoietin-responsive stem cell compartment.
    Ward HP; Vautrin R; Kurnick J; Robinson WA
    Proc Soc Exp Biol Med; 1974 Oct; 147(1):305-8. PubMed ID: 4531056
    [No Abstract]   [Full Text] [Related]  

  • 12. Phagocytosis in myeloproliferative disorders.
    Corberand J; LaHarrague P; De Larrard B; Nguyen F; Pris J
    Am J Clin Pathol; 1980 Sep; 74(3):301-5. PubMed ID: 6932175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The myeloproliferative disorders. Correlation between clinical evolution and alterations of granulopoiesis.
    Greenberg P; Mara B; Bax I; Brossel R; Schrier S
    Am J Med; 1976 Dec; 61(6):878-91. PubMed ID: 1087534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular growth factors in polycythemia vera and other myeloproliferative disorders.
    Eid J; Ebert RF; Gesell MS; Spivak JL
    Proc Natl Acad Sci U S A; 1987 Jan; 84(2):532-6. PubMed ID: 3467372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of murine JAK2V617F-positive myeloproliferative disease.
    Bumm TG; Elsea C; Corbin AS; Loriaux M; Sherbenou D; Wood L; Deininger J; Silver RT; Druker BJ; Deininger MW
    Cancer Res; 2006 Dec; 66(23):11156-65. PubMed ID: 17145859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End-stage renal disease following polycythemia vera: in vitro and in vivo response of erythroid progenitors to erythropoietin and effects of sera on normal erythropoiesis.
    Shih LY; Huang JY
    Nephron; 1998; 79(2):142-7. PubMed ID: 9647492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous platelet aggregation in myeloproliferative disorders. A preliminary study.
    Barbui T; Battista R; Dini E
    Acta Haematol; 1973; 50(1):25-9. PubMed ID: 4200801
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences among myeloproliferative disorders in the behavior of their restricted progenitor cells in culture.
    Croizat H; Amato D; McLeod DL; Eskinazi D; Axelrad AA
    Blood; 1983 Sep; 62(3):578-84. PubMed ID: 6603877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
    Murphy S; Davis JL; Walsh PN; Gardner FH
    Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders.
    Sayinalp N; Cinar H; Uner A; Haznedaroğlu IC; Büyükaşik Y; Göker H; Aksu S; Ozcebe OI; Karakuş S; Kirazli S; Dündar SV
    Clin Lab Haematol; 2004 Aug; 26(4):265-8. PubMed ID: 15279663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.